A PHASE IIa, DOUBLE-BLINDED, MULTI-CENTER, RANDOMIZED STUDY TO ASSESS THE SAFETY,TOLERABILITY, AND PRELIMINARY EFFICACY OF A SINGLE INTRAVENOUS DOSE OF ALLOGENEIC MESENCHYMAL BONE MARROW CELLS TO SUBJECTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

Trial Profile

A PHASE IIa, DOUBLE-BLINDED, MULTI-CENTER, RANDOMIZED STUDY TO ASSESS THE SAFETY,TOLERABILITY, AND PRELIMINARY EFFICACY OF A SINGLE INTRAVENOUS DOSE OF ALLOGENEIC MESENCHYMAL BONE MARROW CELLS TO SUBJECTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Ischemia-tolerant mesenchymal stem cells (Primary)
  • Indications Cardiomyopathies; Myocardial infarction
  • Focus Adverse reactions
  • Sponsors Stemedica Cell Technologies
  • Most Recent Events

    • 25 Apr 2017 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
    • 02 Dec 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 08 Apr 2014 According to ClinicalTrials.gov record, the high and low dose arms of Ischemia tolerant mesenchymal stem cells are combined to form a single treatment arm; hence the treatment arms are reduced to two.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top